Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy

Author(s): Laura de Girolamo, Enrico Lucarelli, Giulio Alessandri, Maria Antonietta Avanzini, Maria Ester Bernardo, Ettore Biagi, Anna Teresa Brini, Giovanna D’Amico, Franca Fagioli, Ivana Ferrero, Franco Locatelli, Rita Maccario, Mario Marazzi, Ornella Parolini, Augusto Pessina, Maria Luisa Torre ; Italian Mesenchymal Stem Cell Group (GISM)

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 13 , 2013

Become EABM
Become Reviewer


Mesenchymal stem cells (MSCs) were first isolated more than 50 years ago from the bone marrow. Currently MSCs may also be isolated from several alternative sources and they have been used in more than a hundred clinical trials worldwide to treat a wide variety of diseases. The MSCs mechanism of action is undefined and currently under investigation. For in vivo purposes MSCs must be produced in compliance with good manufacturing practices and this has stimulated research on MSCs characterization and safety. The objective of this review is to describe recent developments regarding MSCs properties, physiological effects, delivery, clinical applications and possible side effects.

Keywords: Mesenchymal stem/stromal cells, cell therapy, graft versus host disease, immunomodulatory properties, regenerative medicine, advanced therapy medicinal product, transplantation, MSCs sources, clinical trials, clinical applications

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [2459 - 2473]
Pages: 15
DOI: 10.2174/1381612811319130015

Article Metrics

PDF: 80